Translational and Clinical Pharmacology

Korean Society for Clinical Pharmacology and Therapeutics (대한임상약리학회)
권호 표지
DOI QR코드

DOI QR Code

Pharmacodynamic principles and target concentration intervention

  • Holford, Nick (Department of Pharmacology & Clinical Pharmacology, University of Auckland)
  • Published : 2018.12.15
⟨ Previous Next ⟩

Abstract

This tutorial reviews the principles of dose individualisation with an emphasis on target concentration intervention (TCI). Once a target effect is chosen then pharmacodynamics can predict the target concentration and pharmacokinetics can predict the target dose to achieve the required response. Dose individualisation can be considered at three levels: population, group and individual. Population dosing, also known as fixed dosing or "one size fits all" is often used but is poor clinical pharmacology; group dosing uses patient features such as weight, organ function and comedication to adjust the dose for a typical patient; individual dosing uses observations of patient response to inform about pharmacokinetic and pharmacodynamics in the individual and use these individual differences to individualise dose.

Keywords

References

  1. Holford NH. Target concentration intervention: beyond Y2K. Br J Clin Pharmacol 1999;48:9-13. https://doi.org/10.1046/j.1365-2125.1999.00971.x
  2. Holford N. Pharmacodynamic principles and the time course of immediate drug effects. Transl Clin Pharmacol 2017;25:157-161. https://doi.org/10.12793/tcp.2017.25.4.157
  3. Holford N, Yim DS. Clearance. Transl Clin Pharmacol 2015;23:42-45. https://doi.org/10.12793/tcp.2015.23.2.42
  4. Holford N, Yim DS. Volume of distribution. Transl Clin Pharmacol 2016;24:74-77. https://doi.org/10.12793/tcp.2016.24.2.74
  5. New Zealand Formulary. Morphine monograph https://nzf.org.nz/nzf_2515.2019.
  6. Holford NH, Ma SC, Anderson BJ. Prediction of morphine dose in humans. Paediatr Anaesth 2012;22:209-222. doi: 10.1111/j.1460-9592.2011.03782.x.
  7. Holford N, Black P, Couch R, Kennedy J, Briant R. Theophylline target concentration in severe airways obstruction - 10 or 20 mg/L? A randomised concentration-controlled trial. Clin Pharmacokinet 1993;25:495-505. https://doi.org/10.2165/00003088-199325060-00007
  8. Holford N, Hashimoto Y, Sheiner LB. Time and theophylline concentration help explain the recovery of peak flow following acute airways obstruction. Population analysis of a randomised concentration controlled trial. Clin Pharmacokinet 1993;25:506-515. https://doi.org/10.2165/00003088-199325060-00008
  9. Holford N. Pharmacokinetic variability due to environmental differences. Transl Clin Pharmacol 2017;25:59-62. https://doi.org/10.12793/tcp.2017.25.2.59
  10. Peeters MY, Allegaert K, Blusse van Oud-Alblas HJ, Cella M, Tibboel D, Danhof M, et al. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixedexponent allometric model. Clin Pharmacokinet 2010;49:269-275. doi: 10.2165/11319350-000000000-00000.
  11. Holford NH, Buclin T. Safe and effective variability - a criterion for dose individualization. Ther Drug Monit 2012;34:565-568. doi: 10.1097/FTD.0b013e31826aabc3.
  12. Sheiner L, Tozer T. Clinical pharmacokinetics: The use of plasma concentrations of drugs. Clinical Pharmacology: Basic Principles of Therapeutics. Melmon K, Morelli H. New York, Macmillan. 1978;71-109.
  13. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 1972;5:441-459. https://doi.org/10.1016/0010-4809(72)90051-1
  14. Hale MD, Nicholls AJ, Bullingham RE, Hene R, Hoitsma A, Squifflet JP, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998;64:672-683. https://doi.org/10.1016/S0009-9236(98)90058-3
  15. Le Meur Y, Buchler M, Thierry A, Caillard S, Villemain F, Lavaud S, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007;7:2496-2503. https://doi.org/10.1111/j.1600-6143.2007.01983.x
  16. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999;68:261-266. https://doi.org/10.1097/00007890-199907270-00018
  17. Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, et al. Fixedor controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant 2009;9:1607-1619. doi: 10.1111/j.1600-6143.2009.02668.x.

Cited by

  1. Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice vol.71, pp.4, 2018, https://doi.org/10.5937/arhfarm71-32901
  2. Reinforcement learning and Bayesian data assimilation for model‐informed precision dosing in oncology vol.10, pp.3, 2021, https://doi.org/10.1002/psp4.12588
  3. Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity vol.109, pp.4, 2018, https://doi.org/10.1002/cpt.2190
  4. Key Challenges in Providing Effective Antibiotic Therapy for Critically Ill Patients with Bacterial Sepsis and Septic Shock vol.109, pp.4, 2018, https://doi.org/10.1002/cpt.2203
  5. PBPK Modeling and Simulation and Therapeutic Drug Monitoring: Possible Ways for Antibiotic Dose Adjustment vol.9, pp.11, 2021, https://doi.org/10.3390/pr9112087
  6. Pharmacometabolomics-guided clozapine therapy in treatment resistant schizophrenia: Preliminary exploration of future too near vol.67, pp.None, 2022, https://doi.org/10.1016/j.ajp.2021.102939